Payment overview · 2025
General Payments
$961.30
43 reported records · 15 companies
Healthcare provider profile · identity verified
Onyema E Amakiri, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · EL PASO, TX · NPI 1811166721
Verified facts
What the public records show
CMS Open Payments records show Onyema E Amakiri, D.O. received $961.30 in general payments during 2025 across 43 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Mounjaro, Ozempic, Rybelsus, Xifaxan.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 223 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 273 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Nuedexta by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Xifaxan by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $223.78 | 23.3% | 8 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $163.59 | 17.0% | 6 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $110.61 | 11.5% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $72.82 | 7.6% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.84 | 6.8% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $57.45 | 6.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $51.90 | 5.4% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.58 | 5.4% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $45.34 | 4.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.56 | 2.5% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $24.54 | 2.5% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $23.62 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.28 | 1.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.30 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.09 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $879.81 | 42 |
| Education | $81.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $177.63 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $155.73 | 4 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $110.61 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $82.10 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $81.07 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $72.82 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $69.66 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $47.08 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $45.34 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $24.56 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $17.28 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.30 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.73 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.57 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.57 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 273 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 96 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 250 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 50 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 124 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 71 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
223 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
273 | 61 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
250 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
250 | 51 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
50 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
124 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
71 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
113 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
80 | 12 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
96 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2525 | 452 |
| Levothyroxine Sodium | Levothyroxine Sodium | 2181 | 332 |
| Lisinopril | Lisinopril | 1466 | 266 |
| Metformin Hcl | Metformin Hcl | 1404 | 264 |
| Amlodipine Besylate | Amlodipine Besylate | 1244 | 203 |
| Memantine Hcl | Memantine Hcl | 1186 | 113 |
| Eliquis | Apixaban | 1107 | 134 |
| Gabapentin | Gabapentin | 1048 | 218 |
| Famotidine | Famotidine | 1022 | 152 |
| Tamsulosin Hcl | Tamsulosin Hcl | 1005 | 159 |
| Furosemide | Furosemide | 917 | 169 |
| Sertraline Hcl | Sertraline Hcl | 906 | 132 |
| Metoprolol Tartrate | Metoprolol Tartrate | 832 | 127 |
| Trazodone Hcl | Trazodone Hcl | 818 | 136 |
| Hydralazine Hcl | Hydralazine Hcl | 749 | 128 |
| Buspirone Hcl | Buspirone Hcl | 740 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 732 | 174 |
| Simvastatin | Simvastatin | 728 | 122 |
| Mirtazapine | Mirtazapine | 693 | 101 |
| Losartan Potassium | Losartan Potassium | 669 | 152 |
| Donepezil Hcl | Donepezil Hcl | 640 | 71 |
| Omeprazole | Omeprazole | 577 | 130 |
| Carvedilol | Carvedilol | 525 | 107 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 502 | 113 |
| Levetiracetam | Levetiracetam | 469 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 432 | 67 |
| Finasteride | Finasteride | 431 | 50 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 427 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 426 | 92 |
| Nifedipine Er | Nifedipine | 400 | 87 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 398 | 73 |
| Alendronate Sodium | Alendronate Sodium | 377 | 94 |
| Montelukast Sodium | Montelukast Sodium | 373 | 65 |
| Lactulose | Lactulose | 344 | 118 |
| Azithromycin | Azithromycin | 310 | 234 |
| Escitalopram Oxalate | Escitalopram Oxalate | 288 | 49 |
| Potassium Chloride | Potassium Chloride | 282 | 73 |
| Farxiga | Dapagliflozin Propanediol | 273 | 61 |
| Tramadol Hcl | Tramadol Hcl | 263 | 75 |
| Metoclopramide Hcl | Metoclopramide Hcl | 262 | 38 |
| Januvia | Sitagliptin Phosphate | 261 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 257 | 63 |
| Allopurinol | Allopurinol | 254 | 42 |
| Jardiance | Empagliflozin | 250 | 51 |
| Sucralfate | Sucralfate | 246 | 41 |
| Divalproex Sodium | Divalproex Sodium | 245 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 237 | 23 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 225 | 24 |
| Enulose | Lactulose | 224 | 90 |
| Spironolactone | Spironolactone | 224 | 48 |
| Myrbetriq | Mirabegron | 223 | 28 |
| Baclofen | Baclofen | 220 | 29 |
| Midodrine Hcl | Midodrine Hcl | 219 | 56 |
| Ondansetron Hcl | Ondansetron Hcl | 210 | 91 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 207 | 21 |
| Tradjenta | Linagliptin | 198 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 188 | 81 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 184 | 93 |
| Xarelto | Rivaroxaban | 179 | 27 |
| Prednisone | Prednisone | 176 | 99 |
| Sevelamer Carbonate | Sevelamer Carbonate | 173 | 26 |
| Clonazepam | Clonazepam | 171 | 25 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 169 | 40 |
| Oxybutynin Chloride | Oxybutynin Chloride | 168 | 29 |
| Budesonide | Budesonide | 166 | 34 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 166 | 58 |
| Risperidone | Risperidone | 166 | 21 |
| Meclizine Hcl | Meclizine Hcl | 160 | 48 |
| Sodium Chloride | 0.9 % Sodium Chloride | 156 | 79 |
| Fluticasone Propionate | Fluticasone Propionate | 155 | 52 |
| Pregabalin | Pregabalin | 149 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 146 | 18 |
| Oxcarbazepine | Oxcarbazepine | 145 | 18 |
| Lamotrigine | Lamotrigine | 144 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 139 | 44 |
| Zolpidem Tartrate | Zolpidem Tartrate | 136 | 43 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 131 | 15 |
| Lacosamide | Lacosamide | 126 | 17 |
| Ozempic | Semaglutide | 124 | 30 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 122 | 33 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 121 | 36 |
| Fenofibrate | Fenofibrate Nanocrystallized | 121 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 119 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 115 | 17 |
| Linzess | Linaclotide | 113 | 39 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 113 | suppressed |
| Glipizide | Glipizide | 112 | 30 |
| Benztropine Mesylate | Benztropine Mesylate | 111 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 110 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 110 | 22 |
| Torsemide | Torsemide | 107 | 16 |
| Amoxicillin | Amoxicillin | 104 | 93 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 103 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 102 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 100 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 24 |
| Gemtesa | Vibegron | 96 | suppressed |
| Glimepiride | Glimepiride | 94 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 92 | 22 |
| Topiramate | Topiramate | 92 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 19 |
| Propranolol Hcl | Propranolol Hcl | 89 | 13 |
| Valsartan | Valsartan | 81 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 80 | suppressed |
| Lorazepam | Lorazepam | 80 | 24 |
| Xifaxan | Rifaximin | 80 | 12 |
| Fluconazole | Fluconazole | 79 | 62 |
| Silodosin | Silodosin | 79 | suppressed |
| Carbamazepine | Carbamazepine | 77 | suppressed |
| Cephalexin | Cephalexin | 77 | 62 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 77 | 24 |
| Scopolamine | Scopolamine | 77 | 17 |
| Levofloxacin | Levofloxacin | 76 | 62 |
| Aripiprazole | Aripiprazole | 75 | 15 |
| Meloxicam | Meloxicam | 74 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 72 | 15 |
| Rybelsus | Semaglutide | 71 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 70 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 69 | 38 |
| Digoxin | Digoxin | 69 | suppressed |
| Primidone | Primidone | 67 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 66 | 32 |
| Cilostazol | Cilostazol | 63 | 12 |
| Phenobarbital | Phenobarbital | 63 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 62 | 54 |
| Latanoprost | Latanoprost | 60 | 15 |
| Calcitriol | Calcitriol | 58 | suppressed |
| Dexamethasone | Dexamethasone | 58 | 56 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 57 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 55 | 31 |
| Nystatin | Nystatin | 55 | 31 |
| Solifenacin Succinate | Solifenacin Succinate | 55 | 11 |
| Insulin Aspart Flexpen | Insulin Aspart | 54 | 19 |
| Alprazolam | Alprazolam | 53 | 13 |
| Tresiba Flextouch U-100 | Insulin Degludec | 53 | 20 |
| Atenolol | Atenolol | 52 | suppressed |
| Glipizide Er | Glipizide | 52 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 52 | suppressed |
| Cefdinir | Cefdinir | 51 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 50 | 45 |
| Mounjaro | Tirzepatide | 50 | 15 |
| Metolazone | Metolazone | 49 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 48 | 28 |
| Dapagliflozin | Dapagliflozin Propanediol | 48 | 20 |
| Lidocaine | Lidocaine | 48 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 48 | 48 |
| Kerendia | Finerenone | 47 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 47 | 12 |
| Telmisartan | Telmisartan | 47 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 46 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 11 |
| Fenofibrate | Fenofibrate,micronized | 44 | suppressed |
| Glucagon Emergency Kit | Glucagon | 44 | 28 |
| Temazepam | Temazepam | 44 | 12 |
| Vascepa | Icosapent Ethyl | 44 | suppressed |
| Calcium Acetate | Calcium Acetate | 43 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 43 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 27 |
| Ezetimibe | Ezetimibe | 42 | 16 |
| Levemir Flexpen | Insulin Detemir | 41 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 15 |
| Methocarbamol | Methocarbamol | 40 | 18 |
| Moxifloxacin | Moxifloxacin Hcl | 40 | 32 |
| Olanzapine | Olanzapine | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 39 | 32 |
| Tolterodine Tartrate | Tolterodine Tartrate | 39 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 38 | 16 |
| Timolol Maleate | Timolol Maleate | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 37 | 23 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 37 | suppressed |
| Ramelteon | Ramelteon | 37 | suppressed |
| Clonidine | Clonidine | 36 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 36 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 35 | 14 |
| Irbesartan | Irbesartan | 34 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 34 | suppressed |
| Ranolazine Er | Ranolazine | 34 | suppressed |
| Ciclopirox | Ciclopirox | 33 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 33 | suppressed |
| Metronidazole | Metronidazole | 33 | 29 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 25 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 33 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 32 | 15 |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 32 | 12 |
| Methimazole | Methimazole | 32 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Valproic Acid | Valproic Acid | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 24 |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 29 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 22 |
| Brilinta | Ticagrelor | 28 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 28 | suppressed |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | 19 |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 11 |
| Acyclovir | Acyclovir | 26 | 13 |
| Folic Acid | Folic Acid | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 25 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 25 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Entacapone | Entacapone | 24 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 11 |
| Ketoconazole | Ketoconazole | 24 | suppressed |
| Risperidone Er | Risperidone Microspheres | 24 | suppressed |
| Sure Comfort Alcohol | Alcohol Antiseptic Pads | 24 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Methotrexate | Methotrexate Sodium | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Paliperidone Er | Paliperidone | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | 11 |
| Clotrimazole | Clotrimazole | 21 | 16 |
| Enoxaparin Sodium | Enoxaparin Sodium | 21 | 15 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 21 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 12 |
| Novolog | Insulin Aspart | 20 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 20 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 15 |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 19 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Captopril | Captopril | 18 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 18 | 16 |
| Misoprostol | Misoprostol | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | 11 |
| Nuplazid | Pimavanserin Tartrate | 17 | suppressed |
| Nystop | Nystatin | 17 | 14 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 16 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 16 | suppressed |
| Meropenem | Meropenem | 16 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Glucagen | Glucagon | 15 | 12 |
| Prednisolone Acetate | Prednisolone Acetate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 14 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 14 | 11 |
| Acetylcysteine | Acetylcysteine | 13 | suppressed |
| Admelog | Insulin Lispro | 13 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 13 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 13 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $961.30 · 43 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AUSTEDO XR, FARXIGA, GEMTESA, JARDIANCE, Kerendia, MOUNJARO, Nayzilam, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, VOQUEZNA, Veozah, Wegovy, XIFAXAN, YUPELRI, ZEPBOUND | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error